Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 2 of 2 results for mavacamten

  1. Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy (TA913)

    Evidence-based recommendations on mavacamten (Camzyos) for symptomatic obstructive hypertrophic cardiomyopathy.

    Technology appraisal guidance
    Published
    6 September 2023
    View recommendations

    Sections for TA913

  2. First treatment to target heart condition set to benefit thousands as NICE draft guidance approves NHS use

    NICE has approved mavacamten, the first treatment that specifically targets a heart condition called obstructive hypertrophic cardiomyopathy (HCM). It means around 7,000 people will now be able to access the treatment on the NHS.

    News
    Published
    2 June 2023